ClinicalTrials.gg
CompletedNCT05034042StarlightUpdated Oct 26, 2024

A Study to Find the Best Dose of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause

A Phase 2 interventional study of Fezolinetant and Placebo in Hot Flashes, sponsored by Astellas Pharma Inc. Completed at 40 sites in Japan. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by Astellas Pharma Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing fezolinetant in Hot Flashes — 4 open to participants now, 5 under way, 4 of them phase 3. fezolinetant · Hot Flashes.

Enrollment
13th of 16
147 · median 249
Started
2021
the only one that year
Phase 2
5 of 16
1 open now
Registered
7th of 16
by date
Lead sponsor
4 of 16
Astellas Pharma Inc

Among the 16 studies testing fezolinetant in Hot Flashes, this one is the 13th largest by enrollment, is the only one that started in 2021, is one of 5 in phase 2, and was the 7th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

4 of the 16 studies testing fezolinetant in Hot Flashes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About fezolinetant

fezolinetant: first FDA approval 2023 (VEOZAH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing fezolinetant in Hot Flashes, or all of them as a file.
02

Study summary

This study is for menopausal women who have hot flashes. Menopause, a normal part of life, is the time after a woman's last period. Hot flashes often occur during menopause. They can disrupt a woman's daily life. This study will take place in Japan.

This study will provide more information on a potential new treatment, called fezolinetant. The treatments in this study are fezolinetant or a placebo. In this study, a placebo is a dummy treatment that looks like fezolinetant but does not have any medicine in it. The study will compare fezolinetant with the placebo to find the best dose of fezolinetant to reduce the number and severity of hot flashes.

Women that want to take part in the study will be given an electronic handheld device to track their hot flashes. In the last 10 days before their next clinic visit, the women will record information about their hot flashes. Women will be picked for 1 of 3 treatments (lower or higher dose of fezolinetant, or placebo) by chance alone.

Women who take part in the study will take 2 tablets every day for 12 weeks. Treatment will be double-blinded. That means that the women in the study and the study doctors will not know who takes which of the study medicines (lower or higher dose of fezolinetant, or placebo). The women will continue recording information about their hot flashes on the electronic device. They will also use another device to answer questions about how hot flashes affect their daily life.

During the study, the women will visit their study clinic several times for a check-up. This will happen during weeks 2, 4, 8, 12 and 15. At the check-up, they will be asked if they have any medical problems. Other checks will include some blood samples taken for laboratory tests. At some check-ups, the women will have a physical exam, an ECG to check their heart rhythm, and their vital signs checked (pulse rate, temperature and blood pressure). At the first visit and in week 15, women who have a uterus will also have a test called a transvaginal ultrasound. A probe is gently placed inside the vagina. Sound waves will create a picture of the organs in the pelvis. This will allow the study doctor to look more closely at the uterus and surrounding organs.

The last check-up (at week 15) will be 3 weeks after they take their last tablets of study medicine (lower or higher dose of fezolinetant or placebo).

03

Conditions studied

  • Hot Flashes

Browse trials for

Keywords

  • Vasomotor Symptoms (Hot Flashes) Associated with Menopause
  • ESN364
  • fezolinetant
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has a ≥ 16 kg/m\^2 and ≤ 38 kg/m\^2 at screening visit.
  • Subject must be seeking treatment or relief for vasomotor symptoms (VMS) associated with menopause and confirmed as menopausal per 1 of the following criteria at the screening visit:

For subjects:

  • Spontaneous amenorrhea for ≥ 12 consecutive months
  • Spontaneous amenorrhea for ≥ 6 months with biochemical criteria of menopause (follicle-stimulating hormone [FSH] > 40 IU/L); or
  • Having had bilateral oophorectomy ≥ 6 weeks prior to the screening visit (with or without hysterectomy)

For peri-menopausal subjects:

  • Skipped menstrual period with amenorrhea for ≥ 60 days but \< 6 consecutive months with biochemical criteria of peri-menopause (FSH > 25 IU/L); or
  • Spontaneous amenorrhea for ≥ 6 months but \< 12 consecutive months with biochemical criteria of peri-menopause (FSH > 25 IU/L and ≤ 40 IU/L)

    • Within the 10 days prior to randomization, subject must have a minimum average of 7 mild, moderate and severe hot flashes (VMS) per day.
    • Subject is not pregnant and at least 1 of the following conditions apply:
  • Not a woman of (WOCBP)
  • WOCBP who agrees to follow the guidance from the time of through at least 21 days after the final study treatment administration

    • Subject must agree not to breastfeed starting at screening and throughout the study period and for 21 days after the final study treatment administration.
    • Subject must not donate ova starting at first dose of product (IP) and throughout the study period and for 21 days after the final study treatment administration.
    • Subject is in good general health as determined on the basis of medical history and general physical examination, including a bimanual clinical pelvic examination and clinical breast examination devoid of relevant clinical findings, performed at the screening visit; hematology and biochemistry parameters, pulse rate and/or blood pressure, and (ECG) within the reference range for the population studied, or showing no deviations.
    • Subject has documentation of a normal/negative or no clinically significant abnormal findings on breast imaging (obtained at screening or within the prior 12 months of screening). Appropriate documentation includes a written report or an electronic report indicating normal/negative or no clinically significant abnormal findings on breast imaging.
    • Subject is willing to undergo a transvaginal ultrasound (TVU) to evaluate the uterus and ovaries at screening and week 12 (end of treatment), and for subjects who are withdrawn from the study prior to completion, a TVU at the early discontinuation visit. This is not required for subjects who have had a partial (supra-cervical) or full hysterectomy.
    • Subject is willing to undergo endometrial at any time during the study in the case of uterine bleeding. This is not required for subjects who have had a partial (supra-cervical) or full hysterectomy and for peri-menopausal subjects in case of menstrual bleeding.
    • Subject has documentation of a normal or not clinically significant abnormal Pap test (or equivalent cervical cytology) within the previous 12 months of screening or at screening. This is not required for subjects who have had a full trachelectomy.
    • Subject has a negative urine pregnancy test at screening. Urine pregnancy test is not required for female subjects who are assessed as post-menopausal status.
    • Subject has negative serology panel (i.e. negative surface [HBs] antigen) and negative virus [HCV] antibody) at screening.
    • Subject agrees not to participate in another interventional study while participating in the present study.

Exclusion criteria

Exclusion Criteria:

  • Subject uses a prohibited therapy (strong or moderate cytochrome P450 1A2 [CYP1A2] inhibitors, hormone replacement therapy [HRT], hormonal or any treatment for VMS [prescription, over the counter, or herbal/Chinese medicine]) or is not willing to wash out and discontinue use of such drugs for the full duration of study conduct or it is not medically appropriate to discontinue such drugs for the duration of the study.
  • Subject has known substance abuse or alcohol addiction within 6 months of screening.
  • Subject has a history of a malignant tumor except for non- basal cell carcinoma of the skin.
  • Subject has uncontrolled hypertension.
  • Subject has a history of severe allergy, , or intolerance to drugs in general, including the IP and any of its .
  • For subjects with a uterus: Subject has an unacceptable result from the TVU assessment at screening, (i.e., full length of endometrial cavity cannot be visualized or presence of a abnormal finding).
  • Subject has a history of an undiagnosed uterine bleeding within the previous 6 months of screening.
  • Subject has a history of seizures or other convulsive disorders.
  • Subject has a medical condition or chronic disease (including history of neurological [including cognitive], hepatic, renal, cardiovascular, gastrointestinal, pulmonary [e.g., moderate asthma], endocrine, or gynecological disease) or that could confound interpretation of the study outcome.
  • Subject has active liver disease, jaundice, or elevated liver aminotransferases ( [ALT] or aspartate aminotransferase [AST]), elevated total or direct , elevated (INR), or elevated alkaline phosphatase (ALP) at screening. Subject with mildly elevated ALT or AST up to \< 1.5 × the (ULN) can be enrolled if total and direct bilirubin are normal. Subject with mildly elevated ALP (up to \< 1.5 × ULN) can be enrolled if cholestatic liver disease is excluded and no cause other than fatty liver is diagnosed. Subject with Gilbert's syndrome with elevated total bilirubin (TBL) may be enrolled as long as direct bilirubin (DBL), and reticulocytes are normal.
  • Subject has creatinine > 1.5 × ULN; or estimated (eGFR) using the Modification of Diet in Renal Disease formula ≤ 59 mL/min/1.73 m\^2 at screening visit.
  • Subject has a previous positive test for the .
  • Subject has a history of suicide attempt or suicidal behavior within the prior to 12 months of study enrollment or has suicidal ideation within the prior to 12 months of study enrollment (a response of "yes" to question 4 or 5 on the suicidal ideation portion of the Columbia Suicide Severity Rating Scale [C-SSRS]), or who is at significant risk to commit suicide at screening and at visit 2.
  • Subject has had previous exposure with fezolinetant.
  • Subject has received an IP within 28 days or 5 half-lives, whichever is longer, prior to screening.
  • Subject is unable or unwilling to complete the study procedures.
  • Subject has any condition which makes the subject unsuitable for study participation.
  • Subject or relative is the investigator or other site staff directly involved in the conduct of the study.
  • Subject is an employee of the sponsor, contract research organizations (CROs) or site management organizations (SMOs).
  • Present or previous history of participation in a study of the IP.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
147 participants (actual)

Study arms

  • Experimental
    Fezolinetant: low dose (15 mg)

    Participants will receive low dose of fezolinetant once daily for 12 weeks.

    Drug: Fezolinetant

  • Experimental
    Fezolinetant: high dose (30 mg)

    Participants will receive high dose of fezolinetant once daily for 12 weeks.

    Drug: Fezolinetant

  • Placebo comparator
    Placebo

    Participants will receive matching placebo once daily for 12 weeks.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in the frequency of mild, moderate and severe vasomotor symptom (VMS)

    Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Mean change from baseline in the frequency of mild, moderate and severe VMS

    Frequency of mild, moderate or severe VMS events will be calculated as the sum of mild, moderate or severe VMS events per day.

    Time frame: Baseline and up to Week 12

  2. Number of participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a subject administered an investigational product (IP), and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IP whether or not considered related to the IP.

    Time frame: Up to Week 15

  3. Change from baseline in endometrial thickness

    Endometrial thickness is a measure of how thick the lining of the uterus is. Endometrial thickness will be measured by transvaginal ultrasound (TVU).

    Time frame: Baseline and Week 12

  4. Number of participants with laboratory value abnormalities and/or AEs

    Number of participants with potentially clinically significant laboratory values.

    Time frame: Up to Week 15

  5. Number of participants with vital sign abnormalities and/or AEs

    Number of participants with potentially clinically significant vital sign values.

    Time frame: Up to Week 15

  6. Number of participants with electrocardiogram (ECG) abnormalities and/or AEs

    Number of participants with potentially clinically significant ECG values.

    Time frame: Up to Week 12

  7. Number of participants with suicidal ideation and/or behavior as assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)

    The Columbia-Suicide Severity Rating Scale (C-SSRS) is a clinician administered assessment tool that evaluates suicidal ideation and behavior. Number of participants that have an affirmative response provided to the 5 items for suicidal ideation (1. Wish to be dead, 2. Non-specific active suicidal thoughts, 3. Active suicidal ideation with any methods (not plan) without intent to act, 4. Active suicidal ideation with some intent to act, without specific plan, 5. Active suicidal ideation with specific plan and intent) and/or to the 5 items for suicidal behavior (1. Preparatory acts or behavior, 2. Aborted attempt, 3. Interrupted attempt, 4. Actual attempt, 5. Completed suicide) will be reported.

    Time frame: Up to Week 15

07

Study locations

40 sites
  • Juno Vesta Clinic Hatta
    Matsudo-shi, Chiba, Japan
  • Mori Ladies Clinic
    Fukuoka-shi, Fukuoka, Japan
  • SANO Women's Clinic
    Fukuoka-shi, Fukuoka, Japan
  • Japan Organization of Occupational Health and Safety Kyushu Rosai Hospital
    Kitakyusyu-shi, Fukuoka, Japan
  • Ena Odori Clinic
    Sapporo-shi, Hokkaido, Japan
  • Kotoni Ladies Clinic
    Sapporo-shi, Hokkaido, Japan
  • M's Ladies Clinic
    Sapporo-shi, Hokkaido, Japan
  • Nishikawa Women's Health Clinic
    Sapporo-shi, Hokkaido, Japan
  • Sapporo Medical Center, NTT East Corporation
    Sapporo-shi, Hokkaido, Japan
  • Tonan Hospital
    Sapporo-shi, Hokkaido, Japan
  • Asahi-Clinic
    Takamatsu-shi, Kagawa, Japan
  • Unoki Clinic
    Kagoshima-shi, Kagoshima, Japan
  • Yoshinaga Women's Clinic
    Kagoshima-shi, Kagoshima, Japan
  • Sophia Ladies Clinic
    Sagamihara-shi, Kanagawa, Japan
  • Tawada Ladies Clinic
    Yokohama-shi, Kanagawa, Japan
  • Women's Clinic LUNA Yokohama Motomachi
    Yokohama-shi, Kanagawa, Japan
  • Kyoto City Hospital
    Kyoto-shi, Kyoto, Japan
  • Chieko Yukika Lady's Clinic
    Sendai-shi, Miyagi, Japan
  • Social Medical Care Corporation Hosei-kai Marunouchi Hospital
    Matsumoto-shi, Nagano, Japan
  • Kurashiki Medical Clinic
    Kurashiki-shi, Okayama, Japan
  • GyNet Medical Corporation Minamimorimachi Ladies' Clinic
    Osaka-shi, Osaka, Japan
  • Nomura Clinic Namba
    Osaka-shi, Osaka, Japan
  • jMOG Medical Corporation Tanabe Ladies' Clinic
    Takatsuki-shi, Osaka, Japan
  • Maruyama Memorial General Hospital
    Saitama-shi, Saitama, Japan
  • Omi Medical Center, Social Medical Corporation Seikoukai
    Kusatsu-shi, Shiga, Japan
  • Omihachiman Community Medical Center
    Omihachiman-shi, Shiga, Japan
  • Hamada Hospital
    Chiyoda-ku, Tokyo, Japan
  • Ginza Yoshida Clinic
    Chuo-Ku, Tokyo, Japan
  • Medical Corporation Asbo Tokyo Asbo Clinic
    Chuo-ku, Tokyo, Japan
  • Medical Corp. SEIKOUKAI New Medical Research System Clinic
    Hachioji-shi, Tokyo, Japan
  • Toranomon Womens Clinic
    Minato-ku, Tokyo, Japan
  • Yokokura Clinic
    Minato-ku, Tokyo, Japan
  • Shimamura Memorial Hospital
    Nerima-ku, Tokyo, Japan
  • Yukawa Women's Clinic
    Nishitokyo-shi, Tokyo, Japan
  • Seijo Kinoshita Hospital
    Setagaya-ku, Tokyo, Japan
  • Ikebukuro Clinic
    Toshima-ku, Tokyo, Japan
  • Ikebukuro Metropolitan Clinic
    Toshima-ku, Tokyo, Japan
  • Kurobe City Hospital
    Kurobe-shi, Toyama, Japan
  • Japan Organization of Occupational Health and Safety Toyama Rosai Hospital
    Uozu-shi, Toyama, Japan
  • Japan Community Healthcare Organization Tokuyama Central Hospital
    Shunan-shi, Yamaguchi, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Nov 2022, 11 months.

Of 24 phase 2 interventional studies under Hot Flashes, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2021
First posted
Sep 5, 2021
StartActual
Nov 17, 2021
Primary completionActual
Nov 11, 2022
CompletionActual
Dec 23, 2022
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05034042
Responsible party
Sponsor
First posted
Sep 5, 2021
Start date
Nov 17, 2021
Primary completion
Nov 11, 2022
Completion
Dec 23, 2022
Last update
Oct 26, 2024

Study contacts

Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fezolinetant

Start the discussion